Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABX464-103

60 evidence topics · 7 sources

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Parallel Assignment”
Model description“Randomized, double blind, placebo controlled, parallel groups”
Masking“Quadruple”
Phase“Phase 2”
Enrollment (actual)“355”
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in modified mayo score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed for the primary outcome in the posted results
GroupParticipants analyzed, change in MMS at week 8
ABX464 100 mg“58”
ABX464 50 mg“54”
ABX464 25 mg“59”
Matching placebo“60”
Description of analysis sets
Results
Participant disposition
Participant flow in the posted results
MeasureABX464 100 mgABX464 50 mgABX464 25 mgMatching placebo
Started“64”“63”“63”“64”
Treated“64”“63”“62”“64”
Full analysis set“64”“63”“61”“64”
Completed“54”“53”“58”“57”
Not completed“10”“10”“5”“7”
Baseline characteristics
Baseline characteristics in the posted results
CharacteristicABX464 100 mgABX464 50 mgABX464 25 mgMatching placeboTotal
Participants“64”“63”“61”“64”“252”
Age, years, mean (SD)“42.2(12.34)”“40.2(13.94)”“41.5(14.16)”“41.1(14.43)”“41.2(13.67)”
Female“23”“36”“21”“24”“104”
Male“41”“27”“40”“40”“148”
Baseline MMS 5 to 6“17”“16”“17”“21”“71”
Baseline MMS 7 to 9“47”“47”“44”“42”“180”
Participants enrolled by country in the posted results, selected countries
CountryTotal participants
Poland“70”
Ukraine“32”
France“30”
Hungary“22”
Italy“20”
United States“2”
Efficacy results
Primary outcome in the posted results: least squares mean change in MMS at week 8
GroupLeast squares mean95% confidence interval
ABX464 100 mg“-2.9”“(-3.4 to -2.5)”
ABX464 50 mg“-3.2”“(-3.7 to -2.7)”
ABX464 25 mg“-3.1”“(-3.6 to -2.6)”
Matching placebo“-1.9”“(-2.4 to -1.5)”
Secondary outcomes at week 8 in the posted results: number of participants
Outcome (participants analyzed per group)ABX464 100 mgABX464 50 mgABX464 25 mgMatching placebo
Clinical remission per MMS (64, 63, 61, 64)“16”“11”“16”“8”
Clinical response (64, 63, 61, 64)“32”“37”“38”“22”
Endoscopic improvement (54, 53, 58, 59)“24”“21”“20”“8”
Endoscopic remission (54, 53, 58, 59)“2”“5”“4”“5”
Mucosal healing (64, 63, 61, 64)“0”“1”“0”“2”
Secondary outcomes at week 16 in the posted results: number of participants
Outcome (participants analyzed per group)ABX464 100 mgABX464 50 mgABX464 25 mgMatching placebo
Clinical remission per MMS (31, 30, 37, 46)“7”“6”“9”“6”
Clinical response (31, 30, 37, 46)“19”“20”“25”“20”
Endoscopic improvement (32, 31, 38, 46)“11”“12”“11”“9”
Endoscopic remission (32, 31, 38, 46)“1”“1”“2”“3”
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

ABX464-103 was a phase 2b, randomized, double-blind, placebo-controlled dose-ranging induction trial with 4 parallel groups; 254 participants were randomized and 252 were included in the full analysis set. The primary endpoint was the change from baseline in modified Mayo score at week 8, and the protocol also defined clinical remission, clinical response, and endoscopic improvement as outcomes. The posted results report the primary outcome for 58, 54, 59, and 60 participants in the 100 mg, 50 mg, 25 mg, and placebo groups, against full analysis set sizes of 64, 63, 61, and 64. The protocol scheduled week 16 endoscopy only for participants without endoscopic improvement at week 8, and the week 16 outcomes were analyzed in participants “with data available for baseline and the respective visit”. The protocol limited participants with previous exposure to biologics or JAK inhibitors to 60%, those with previous vedolizumab to 20%, and those with previous JAK inhibitors to 10%. Of 252 participants, 2 were enrolled in the United States, and race and ethnicity were not collected. The protocol planned IBDQ assessment at Week 8 and Week 16, and no IBDQ results were located in the PubMed abstract or the posted results. Headache was reported in 27 of 64, 19 of 63, 13 of 62, and 5 of 64 participants in the 100 mg, 50 mg, 25 mg, and placebo groups. The PubMed abstract gives NCT04023396, the record of the open-label maintenance study, as the trial registration.